Patent Number: 6,251,388

Title: Utilization of Wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence

Abstract: Described herein are methods for producing recombinant forms of asparaginase derived from Wolinella succinogenes. In addition, methods for covalent modification of proteins, including asparaginases, by acylation are also provided. Certain embodiments provide for epitopic-labeling of the amino terminus of W. succinogenes asparaginase. Additional embodiments concern methods for the therapeutic utilization of the native, homotetrameric form of W. succinogenes asparaginase, as well as the use of epitopically-labeled or non-epitopically-labeled recombinant W. succinogenes asparaginase (or a covalently modified analog thereof) in the therapeutic treatment of malignant and non-malignant hematological disease and other diseases where asparagine depletion or deprivation would be efficacious or which respond to asparagine depletion or deprivation, as well as their potential utilization in the therapeutic treatment of autoimmune diseases such as rheumatoid arthritis, AIDS, and SLE.

Inventors: Durden; Donald L. (Glendale, CA)

Assignee: Childrens Hospital Los Angeles

International Classification: A61K 38/50 (20060101); A61K 38/43 (20060101); C12N 9/82 (20060101); C12N 9/78 (20060101); A61K 38/00 (20060101); A61K 038/46 (); C12N 009/82 (); C12N 001/20 (); C12N 015/09 (); C07H 021/04 ()

Expiration Date: 06/26/2018